Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial-Reference-Cited by-同舟云学术

Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial

Published:2019-04 Issue:4 Volume:39 Page:2053-2059
ISSN:0250-7005
Container-title:Anticancer Research
language:en
Short-container-title:Anticancer Res

Author:

TOKUNAGA SHINYA,TAKASHIMA TSUTOMU,KASHIWAGI SHINICHIRO,NODA SATORU,KAWAJIRI HIDEMI,TOKUMOTO MAO,NISHIMURA SHIGEHIKO,NISHIMORI TAKEO,IKEDA KATSUMI,OGAWA YOSHINARI,MIZUYAMA YOKO,SUNAMI TAKESHI,TEZUKA KENJI,YAMAGATA SHIGEHITO,ISHIKAWA TETSURO,KUDOH SHINZOH,TAKADA MINORU,HIRAKAWA KOSEI,OHIRA MASAICHI

Publisher

Anticancer Research USA Inc.

Subject

Cancer Research,Oncology,General Medicine

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Interval Between Neoadjuvant Chemotherapy and Surgery on Oncological Outcomes in Poor Responders With Locally Advanced Breast Cancer;Journal of Breast Cancer;2024

2. Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer Treatment;Pharmaceuticals;2022-07-17

3. Comparison of adverse effects of trastuzumab with other drug combinations for the treatment of breast cancer: A review;Indian Journal of Physiology and Pharmacology;2022-05-31

4. An efficient synthesis of 6‐arylpyrazolo[4′,3′:4,5]pyrimido[2,1‐a] isoquinolin‐8(9 H )‐one derivatives catalyzed by AgOTf;Journal of Heterocyclic Chemistry;2021-12-19

5. Phase II Study of Nab-paclitaxel Plus Cyclophosphamide Plus Trastuzumab Neoadjuvant Chemotherapy in Early HER-2-positive Breast Cancer;Anticancer Research;2021-07-19